Interferon Beta Enhances the Natural Killer Activity of Patients with Bladder Carcinoma

Overview

Journal Cancer Immunol Immunother

Specialties Allergy & Immunology
Oncology
Pharmacology

Date 1994 Jun 1

PMID 8205562

Authors

L Molto

J Carballido

L Manzano

C Olivier

P Lapena

M Alvarez-Mon

Affiliations

Soon will be listed here.

Abstract

We have investigated the effect of interferon beta (INF beta) on the natural killer (NK) cytotoxic activity of peripheral blood mononuclear cells (PBMC) from patients with superficial and infiltrative transitional-cell carcinoma of the bladder (TCC) against both NK-sensitive and NK-resistant target cells. The normal NK activity found in PBMC from these patients can be significantly enhanced by short-term incubation (18 h) with INF beta (P < 0.05). The depressed NK cytotoxic activity found in PBMC from patients with infiltrative TCC can also be significantly enhanced, but not normalized, by short-term incubation with INF beta (P < 0.05). In kinetic studies we found that the maximal levels of the INF beta-promoted cytotoxic activity against NK-sensitive and against NK-resistant target cells in PBMC from TCC patients were reached after 18 h of culture. Short-term-INF beta-incubated PBMC from patients with TCC of the bladder also showed marked cytotoxic activity against NK-resistant target cells. The effector cells of the INF beta-induced cytotoxic activity in PBMC from patients with TCC were CD16+ CD3- NK cells. This cytotoxic inducer effect of INF beta synergized with that of interleukin-2. In conclusion, INF beta can enhance the NK activity of PMBC from patients with TCC of the bladder.

References

Carballido J, Alvarez-Mon M, Solovera O, Durantez A . Clinical significance of natural killer activity in patients with transitional cell carcinoma of the bladder. J Urol. 1990; 143(1):29-33. DOI: 10.1016/s0022-5347(17)39854-3. View

Mukherji B, CHAKRABORTY N, Sivanandham M . T-cell clones that react against autologous human tumors. Immunol Rev. 1990; 116:33-62. DOI: 10.1111/j.1600-065x.1990.tb00803.x. View

Ortaldo J, Herberman R . Heterogeneity of natural killer cells. Annu Rev Immunol. 1984; 2:359-94. DOI: 10.1146/annurev.iy.02.040184.002043. View

Heo D, Whiteside T, Kanbour A, Herberman R . Lymphocytes infiltrating human ovarian tumors. I. Role of Leu-19 (NKH1)-positive recombinant IL-2-activated cultures of lymphocytes infiltrating human ovarian tumors. J Immunol. 1988; 140(11):4042-9. View

Sancho L, de la Hera A, Casas J, Vaquer S, Martinez C, Alvarez-Mon M . Two different maturational stages of natural killer lymphocytes in human newborn infants. J Pediatr. 1991; 119(3):446-54. DOI: 10.1016/s0022-3476(05)82061-x. View

Rosenberg S, Lotze M, Muul L, Chang A, Avis F, Leitman S . A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone. N Engl J Med. 1987; 316(15):889-97. DOI: 10.1056/NEJM198704093161501. View

Vaquer S, de la Hera A, Jorda J, Martinez C, Escudero M, Alvarez-Mon M . Diminished natural killer activity in pregnancy: modulation by interleukin 2 and interferon gamma. Scand J Immunol. 1987; 26(6):691-8. DOI: 10.1111/j.1365-3083.1987.tb02305.x. View

Raghavan D, Shipley W, Garnick M, Russell P, Richie J . Biology and management of bladder cancer. N Engl J Med. 1990; 322(16):1129-38. DOI: 10.1056/NEJM199004193221607. View

Lotze M, Grimm E, Mazumder A, Strausser J, Rosenberg S . Lysis of fresh and cultured autologous tumor by human lymphocytes cultured in T-cell growth factor. Cancer Res. 1981; 41(11 Pt 1):4420-5. View

10.

Paucker K, Cantell K, Henle W . Quantitative studies on viral interference in suspended L cells. III. Effect of interfering viruses and interferon on the growth rate of cells. Virology. 1962; 17:324-34. DOI: 10.1016/0042-6822(62)90123-x. View

11.

Horoszewicz J, Murphy G . An assessment of the current use of human interferons in therapy of urological cancers. J Urol. 1989; 142(5):1173-80. DOI: 10.1016/s0022-5347(17)39022-5. View

12.

GLASHAN R . A randomized controlled study of intravesical alpha-2b-interferon in carcinoma in situ of the bladder. J Urol. 1990; 144(3):658-61. DOI: 10.1016/s0022-5347(17)39547-2. View

13.

Alvarez de Mon M, Casas J, Laguna R, Toribio M, de Landazuri M, Durantez A . Lymphokine induction of NK-like cytotoxicity in T cells from B-CLL. Blood. 1986; 67(1):228-32. View

14.

Kadish A, Doyle A, Steinhauer E, GHOSSEIN N . Natural cytotoxicity and interferon production in human cancer: deficient natural killer activity and normal interferon production in patients with advanced disease. J Immunol. 1981; 127(5):1817-22. View

15.

Grimm E, Mazumder A, Zhang H, Rosenberg S . Lymphokine-activated killer cell phenomenon. Lysis of natural killer-resistant fresh solid tumor cells by interleukin 2-activated autologous human peripheral blood lymphocytes. J Exp Med. 1982; 155(6):1823-41. PMC: 2186695. DOI: 10.1084/jem.155.6.1823. View

16.

Bonilla F, Alvarez-Mon M, Merino F, de la Hera A, Ales J, Espana P . Interleukin-2 induces cytotoxic activity in lymphocytes from regional axillary nodes of breast cancer patients. Cancer. 1988; 61(4):629-34. DOI: 10.1002/1097-0142(19880215)61:4<629::aid-cncr2820610402>3.0.co;2-v. View

17.

Witjes J, Debruyne F . Optimal management of superficial bladder cancer. Eur J Cancer. 1991; 27(3):330-3. DOI: 10.1016/0277-5379(91)90541-k. View

18.

Morales A, Ottenhof P . Clinical application of a whole blood assay for human natural killer (NK) cell activity. Cancer. 1983; 52(4):667-70. DOI: 10.1002/1097-0142(19830815)52:4<667::aid-cncr2820520417>3.0.co;2-c. View

19.

Niijima T . Intravesical treatment of bladder cancer with recombinant human interferon-beta. Intravesical GKT-beta Chemotherapy Research Group. Cancer Immunol Immunother. 1989; 30(2):81-5. PMC: 11038014. DOI: 10.1007/BF01665957. View

20.

Carballido J, Molto L, Manzano L, Olivier C, Salmeron O, Alvarez de Mon M . Interferon-alpha-2b enhances the natural killer activity of patients with transitional cell carcinoma of the bladder. Cancer. 1993; 72(5):1743-8. DOI: 10.1002/1097-0142(19930901)72:5<1743::aid-cncr2820720538>3.0.co;2-t. View